Eylea Market Report 2026
Global Outlook – By Product (Prefilled Syringe Package, Vial Package), By Disorder (Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Other Disorders), By Application (Hospitals, Retail Pharmacy, Other Applications) – Market Size, Trends, Strategies, and Forecast to 2030
Eylea Market Overview
• Eylea market size has reached to $10.51 billion in 2025 • Expected to grow to $14.79 billion in 2030 at a compound annual growth rate (CAGR) of 7.3% • Growth Driver: Eylea Market Thrives On Addressing The Rise In Ocular Diseases • Market Trend: Aflibercept Biosimilars Paving The Way In Ophthalmology Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.What Is Covered Under Eylea Market?
Eylea is a type of drug injected into the eye that helps slow vision loss and certain other diseases by blocking the leaking and growth of fluid from abnormal blood vessels from the back of the eye. It is used to treat age-related macular degeneration (AMD). The main types of eylea are prefilled syringe packages and vial packages. Prefilled syringe package refers to a type of disposable syringe supplied by already loading the drug. It is used to treat wet age-related macular degeneration (AMD), diabetic retinopathy, and other disorders by hospitals, retail pharmacies, and other applications.
What Is The Eylea Market Size and Share 2026?
The eylea market size has grown strongly in recent years. It will grow from $10.51 billion in 2025 to $11.15 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to rising prevalence of age-related macular degeneration, aging global population, strong clinical efficacy of anti-vegf drugs, increased ophthalmology specialty centers, reimbursement support for retinal therapies.What Is The Eylea Market Growth Forecast?
The eylea market size is expected to see strong growth in the next few years. It will grow to $14.79 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to growing diabetic population, expansion into additional retinal disorders, long-acting formulation development, improved drug delivery formats, increasing access in emerging markets. Major trends in the forecast period include extended-interval anti-vegf therapies, shift toward prefilled syringe adoption, growing use in diabetic retinopathy treatment, increased hospital-based intravitreal procedures, focus on real-world evidence and outcomes.
Global Eylea Market Segmentation
1) By Product: Prefilled Syringe Package, Vial Package 2) By Disorder: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Other Disorders 3) By Application: Hospitals, Retail Pharmacy, Other Applications Subsegments: 1) By Prefilled Syringe Package: Single-Dose Prefilled Syringes, Multi-Dose Prefilled Syringes 2) By Vial Package: Single-Dose Vials, Multi-Dose VialsWhat Is The Driver Of The Eylea Market?
The increasing prevalence of ocular diseases is expected to propel the Eylea market. Ocular diseases refer to an eye condition that interferes with the ability of the eye to properly function and negatively affects the vision and clarity of the eye. They often don't have any symptoms until they have become very advanced. Eylea treats conditions such as ocular diseases, including wet age-related macular degeneration (AMD) and glaucoma, which damages the retina or macula that affects the vision. Eylea blocks the protein that develops new weaker blood vessels and slows down the retina's swelling caused by a blockage in the blood vessels. For instance, in 2024, according to the BrightFocus Foundation, a U.S.-based nonprofit organization focused on macular degeneration and glaucoma research, approximately 80 million people globally are living with glaucoma, and this is projected to rise to 111 million by 2040. Therefore, the increasing prevalence of ocular diseases is driving the Eylea industry.Key Players In The Global Eylea Market
Major companies operating in the eylea market are Regeneron Pharmaceuticals Inc., Bayer AG, Novartis AG, Roche Holding AG, Pfizer Inc., Amgen Inc., Sanofi S.A., AbbVie Inc., Alcon Inc., Genentech Inc., Johnson & Johnson, Samsung Bioepis Co. Ltd., Boehringer Ingelheim GmbH, Eisai Co. Ltd., Daiichi Sankyo Company Limited, Aerie Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Santen Pharmaceutical Co. Ltd., Allergan plc, BioMarin Pharmaceutical Inc.
This chart is for illustrative purposes; the full report includes a detailed competitor analysis and comprehensive overview of the top 10 companies in the market.
This chart maps companies by product innovation and brand strength, with bubble size indicating relative revenue, helping identify market leaders, challengers, and niche players. This is an illustrative chart; the full report provides a complete and accurate competitive analysis.
Explore how leading companies compare across key metrics in our report Get Report
Global Eylea Market Trends and Insights
Major companies operating in the eylea market are focused on developing biologic medications such as aflibercept biosimilar to gain a competitive advantage. An Aflibercept Biosimilar is a biologically similar version of the reference drug aflibercept, designed to have no clinically meaningful differences and offering a cost-effective alternative for the treatment of specific eye conditions. For instance, in September 2023, Biocon Biologics Ltd., an India-based biopharmaceutical company, received marketing authorization from the European Commission (EC) for YESAFILI, a biosimilar of Aflibercept, in the European Union (EU). This approval follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in July. YESAFILI is an ophthalmology product designed for the treatment of various eye conditions, and its approval signifies its comparability in terms of quality, safety, and efficacy to the reference product Eylea (aflibercept).What Are Latest Mergers And Acquisitions In The Eylea Market?
In January 2023, Coherus BioSciences Inc., a US-based biopharmaceutical company, acquired the exclusive commercialization rights to Eylea Biosimilar Candidate from Klinge Biopharma GmbH for $32.5 million. This agreement reinforces the company's dedication to broadening options and enhancing accessibility for physicians and patients in search of high-quality, affordable alternatives to anti-VEGF therapies across the entire spectrum of healthcare. Klinge Biopharma GmbH is a Germany-based pharmaceutical company proving ocular disease drugs such as Eylea Biosilimar.
Regional Insights
North America was the largest region in the eylea market in 2025. Asia-Pacific is expected to be the fastest-growing region in the eylea market during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.Need data for a specific geography? Request Regional Data
What Defines the Eylea Market?
The eylea market consists of sales of single-dose vials and single-dose prefilled syringes of Eylea. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This chart presents market attractiveness based on a quantitative evaluation of growth, competition, strategic alignment, and risk, offering a clear view of opportunity areas for decision-making. This chart is for illustrative purposes; the full report contains the complete analysis.
This chart highlights the Total Addressable Market (TAM) by estimating the maximum revenue opportunity using an assumption-driven approach, supporting strategic planning and opportunity sizing across markets. The chart is illustrative; the full report provides a more comprehensive analysis.
Access full TAM calculations and growth projections in our report Get Report
What Key Data and Analysis Are Included in the Eylea Market Report 2026?
The eylea market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the eylea industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Eylea Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $11.15 billion |
| Revenue Forecast In 2030 | $14.79 billion |
| Growth Rate | CAGR of 6.2% from 2026 to 2030 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2030 |
| Segments Covered | Product, Disorder, Application |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain. |
| Key Companies Profiled | Regeneron Pharmaceuticals Inc., Bayer AG, Novartis AG, Roche Holding AG, Pfizer Inc., Amgen Inc., Sanofi S.A., AbbVie Inc., Alcon Inc., Genentech Inc., Johnson & Johnson, Samsung Bioepis Co. Ltd., Boehringer Ingelheim GmbH, Eisai Co. Ltd., Daiichi Sankyo Company Limited, Aerie Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Santen Pharmaceutical Co. Ltd., Allergan plc, BioMarin Pharmaceutical Inc. |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |